Recent Updates
Recently added Catalysts

TTX-030, nab-paclitaxel and gemcitabine

Phase 2

Pancreatic Cancer | Small molecule | Oncology |AbbVie Inc.|Last Updated: Dec 4, 2024

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedACTIVE_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment194
FDA Designations
No designations recorded
Clinical trial landscape

TTX-030, nab-paclitaxel and gemcitabine · 1 trial · 1 indication

Phase 2 1
NCT06119217Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC PatientsPancreatic Cancer
ACTIVE NOT_RECRUITING194 Analytics
PHASE2ACTIVE NOT_RECRUITING
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
Pancreatic Cancer
NCT06119217194
Unlock trial analytics
Study Endpoints
Primary Endpoints
Progression-free survival (PFS) - Biomarker Enriched Population
Through study completion, an average of 1 year

PFS is defined as the time from randomization until first documentation of progression or death from any cause, whichever occurs first

Secondary Endpoints
Progression-free survival (PFS) - Overall Population
Through study completion, an average of 1 year
Objective Response Rate (ORR)
Through study completion, an average of 1 year
Duration of Response (DoR)
Through study completion, an average of 1 year
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Arm 1EXPERIMENTALTTX-030 plus nab-paclitaxel and gemcitabine
Arm 2EXPERIMENTALTTX-030 plus budigalimab plus nab-paclitaxel and gemcitabine
Arm 3ACTIVE_COMPARATORNab-Paclitaxel and gemcitabine
Interventions
NameTypeDescription
TTX-030, nab-paclitaxel and gemcitabineCOMBINATION_PRODUCTDose and schedule per protocol
TTX-030, budigalimab, nab-paclitaxel and gemcitabineCOMBINATION_PRODUCTDose and schedule per protocol
Nab-Paclitaxel and gemcitabineCOMBINATION_PRODUCTDose and schedule per protocol
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites64

Abbreviated Inclusion Criteria: 1. Age 18 years or older, is willing and able to provide informed consent 2. Histologically or cytologically confirmed diagnosis of metastatic PDAC. 3. No prior systemic treatment for metastatic disease. 4. Evidence of measurable disease per RECIST 1.1. 5. Appropriat...

Countries:United StatesAustraliaFranceItalySouth KoreaSpainTaiwan
Unlock Eligibility Criteria
Competitive Landscape -Pancreatic Cancer 182 trials

Top 20 of 73 competitors

CompanyTickerTrialsLead PhaseDrugs
Revolution Medicines, Inc.RVMD9PHASE3RMC-6236, Gemcitabine, nab-paclitaxel, Irinotecan, Liposomal irinotecan
Arcus Biosciences, Inc.RCUS3PHASE3Quemliclustat, Nab-paclitaxel, Gemcitabine
Pfizer Inc.PFE7PHASE2tisotumab vedotin, pembrolizumab, carboplatin, cisplatin
AstraZeneca PLCAZN9PHASE2AZD0901, 5-Fluorouracil, Leucovorin, l-leucovorin, Irinotecan
AbbVie, Inc.ABBV4PHASE2TTX-030, nab-paclitaxel and gemcitabine, Nab-Paclitaxel and gemcitabine
AngioDynamics, Inc.ANGO2PHASE3Modified FOLFIRINOX Regimen
Bristol-Myers Squibb CompanyBMY4PHASE2Navlimetostat, Gemcitabine, Nab-paclitaxel
Immuneering Corp. Class AIMRX2PHASE3Atebimetinib, GnP, mGnP
RenovoRx, Inc.RNXT1PHASE3Gemcitabine, nab-paclitaxel
BioNTech SE Sponsored ADRBNTX2PHASE2Pumitamig, Nab-paclitaxel, Gemcitabine, mFOLFIRINOX
Veracyte, Inc.VCYT1PHASE3Tislelizumab
Merck & Co., Inc.MRK2PHASE2Belzutifan
ArriVent BioPharma, Inc.AVBP3PHASE2JAB-21822
Eli Lilly and CompanyLLY7PHASE1LY4101174
Exelixis, Inc.EXEL1PHASE2Zanzalintinib, Everolimus
Agenus Inc.AGEN4PHASE2AGEN1423, Botensilimab, Gemcitabine, Nab-paclitaxel
HUTCHMED (China) Limited Sponsored ADRHCM1PHASE2Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine, Nab-paclitaxel Plus Gemcitabine, Surufatinib with Nab-paclitaxel, and Gemcitabine
ImmunityBio IncIBRX2PHASE2N-803, Aldoxorubicin, PD-L1 t-haNK, Nab-paclitaxel, Gemcitabine
Incyte CorporationINCY3PHASE2Ruxolitinib, Capecitabine, Regorafenib
Candel Therapeutics, Inc.CADL1PHASE2Aglatimagene besadenovec
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT06119217studyFirstPostDate: changed